PRIORITY 1
ACCELERATED RIDS PROCESSING

REGULATORY INFORMATION DISTRIBUTION SYSTEM (RIDS)

ACCESSION NBR:9411220327 DOC.DATE: 94/11/15 NOTARIZED: NO DOCKET #
FACIL:50-250 Turkey Point Plant, Unit 3, Florida Power and Light C 05000250
50-251 Turkey Point Plant, Unit 4, Florida Power and Light C 05000251
50-335 St. Lucie Plant, Unit 1, Florida Power & Light Co. 05000335
50-389 St. Lucie Plant, Unit 2, Florida Power & Light Co. 05000389
AUTH.NAME AUTHOR AFFILIATION
BOHLKE,W.H. Florida Power & Light Co.
RECIP.NAME RECIPIENT AFFILIATION
Document Control Branch (Document Control Desk)

SUBJECT: Forwards rept of unsatisfactory performance testing incident.Rept details investigative analysis of unsatisfactory blind specimen result,including cause & C/A taken by SmithKline Beecham Clinical Lab.

DISTRIBUTION CODE: A022D COPIES RECEIVED:LTR 1 ENCL 1 SIZE: 3
TITLE: Fitness for Duty Program: Blind Performance Test/Other

NOTES:

	RECIPIENT ID CODE/NAME	COPIES LTTR	COPIES ENCL	RECIPIENT ID CODE/NAME	COPIES LTTR	COPIES ENCL
	PD2-2 PD	1	1	CROTEAU,R	1	1
	NORRIS,J	1	1			
INTERNAL:	ACRS	1	1	FILE CENTER 01	1	1
	NRR/DRSS/PSGB	1	1	NUDOCS-ABSTRACT	1	1
	RGN2 . 02	1	1			
EXTERNAL:	NOAC	1	1	NRC PDR	1	1

P R I O R I T Y 1 D O C U M E N T

NOTE TO ALL "RIDS" RECIPIENTS:
PLEASE HELP US TO REDUCE WASTE! CONTACT THE DOCUMENT CONTROL DESK, ROOM P1-37 (EXT. 504-2083) TO ELIMINATE YOUR NAME FROM DISTRIBUTION LISTS FOR DOCUMENTS YOU DON'T NEED!

TOTAL NUMBER OF COPIES REQUIRED: LTTR 10 ENCL 10

MA4

Florida Power & Light Company, P.O. Box 14000, Juno Beach, FL 33408-0420

FPL

NOV 1 5 1994

L-94-290
10 CFR 26

U. S. Nuclear Regulatory Commission
Attn: Document Control Desk
Washington, DC 20555

Gentlemen:

Re: Turkey Point Units 3 and 4
Docket Nos. 50-250 and 50-251
St. Lucie Units 1 and 2
Docket Nos. 50-335 and 50-389
10 CFR 26 Unsatisfactory Performance
Testing Incident Report

Pursuant to 10 CFR 26, Appendix A, Section 2.8(e)(4), Florida Power and Light Company (FPL) is submitting to the NRC the enclosed report of an unsatisfactory performance testing incident. FPL submitted blind performance test specimens to FPL's contract Department of Health and Human Services (DHHS) certified laboratory, SmithKline Beecham Clinical Laboratories. The enclosed report details the investigative analysis of the unsatisfactory blind specimen result, the identification of the cause, and the corrective action taken by the laboratory to prevent recurrence.

Please contact us if additional information is required.

Very truly yours,

W. H. Bohlke
Vice President
Nuclear Engineering and Licensing

WHB/spt

Attachment

cc: Stewart D. Ebneter, Regional Administrator, Region II, USNRC
Senior Resident Inspector, USNRC, Turkey Point Plant
Senior Resident Inspector, USNRC, St. Lucie Plant

210066

9411220327 941115
PDR ADOCK 05000250
P PDR

A022
1/1

SmithKline Beecham
Clinical Laboratories

Michael I. Schaffer, Ph.D.

October 29, 1994

Donald Rainone, M.D.
Medical Review Officer
Florida Power & Light
700 Universe Blvd Ste D02224
Juno Beach, FL 33408

RE: SS# 346-29-5363

Dear Dr. Rainono:

An investigation into the above mentioned matter was held with the following results:

1. Specimen 346-29-5363, with requisition number 987769 was received into the toxicology laboratory on October 13, 1994. The specimen was logged in and forwarded to a NRC batch for initial screening on the Hitachi 717 analyzer. The specimen was aliquotted and placed in a rack with other specimens in the batch. The results of the initial test were negative and the specimen which bears the laboratory accession number 191621F was released as a negative on October 13, 1994.

2. A request was received on October 13, 1994 to re-run the specimen. The specimen was re-aliquotted and submitted for initial testing on October 13, 1994. The results were positive for the Opiate category. The specimen was therefore forwarded to GC/MS for confirmation with the results of codeine positive; 543 ng/ml, and morphine positive; 666 ng/ml, respectively.

3. After a careful review of the initial tests which were performed the following were determined:

A. The only conclusion that can be drawn from the results, was that apparently an aliquotting error had occurred, which resulted in two specimens being reversed in the batch. The Florida Power & Light specimen was tested as a clear negative, and the adjacent specimen was tested as a positive. The adjacent specimen was forwarded to GC/MS for confirmation, with the result being negative.

B. Since this is the most likely event to have occurred, we have taken steps to retrain the individual who performed the aliquotting. Six hours of re-training were conducted, with the individual re-reading the aliquotting procedure, and the SOP, as well as spending time with two different individuals who perform aliquotting for remedial training. We have also instituted a series of QC checks in the process. All persons are held responsible for signing off onto a document that they have verified the QC steps and have done everything that is necessary in assuring the process is correct. This is a further check on all individuals, and a way to document all QC checks.

I believe that this is an isolated occurrence, which has been corrected with remedial training for this individual and the long term resolution of adequate QC checks in the process.

801 E. Dixie Avenue, Leesburg, FL 34748 • 800-342-9520

SmithKline Beecham
Clinical Laboratories

Michael I. Schaffer, Ph.D.

If you should have any additional questions surrounding this occurrence, please do not hesitate to write or call at your earliest convenience.

Respectfully yours,

Michael I. Schaffer, Ph.D., D.A.B.F.T.
Director of Toxicology

XC: R. T. Chamberlain, J.D., Ph.D.
Kathe Russell, B.S.
Pat Miller, B.S.
Christine Nyght, Ph.D.

801 E. Dixie Avenue, Leesburg, FL 34748 • 800-342-9520